Recent News
A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific ratesRead Article
FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/fN8pbWtmfT
Links:
Dr. John Cush @RheumNow ( View Tweet)
Missed #RheumNowLive 2026?
The full meeting is now available On Demand.
✔ 2 days of clinical updates
✔ Expert faculty panels
✔ Speaker slides
✔ Pre-learn modules
Watch anytime for $250.
Learn from the meeting that kicks off the year in rheumatology.
🔗 Access here: https://t.co/9dx4bv66BW
Dr. John Cush @RheumNow ( View Tweet)
Poets Know It (3.13.2026)
Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.
https://t.co/gFToRS2xh4 https://t.co/FUIWlNG5QJ
Dr. John Cush @RheumNow ( View Tweet)
Pitfalls of autoimmune serologic testing
Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of serological autoimmune markers.
A current review focuses commonly used serologies and autoimmune tests to identify common pitfalls and a diagnostic workflow when suspecting systemic autoimmune diseases.
Practical points from this review:
Read Article
5 years of an IL–23 inhibitor in bio-naive patients with PsA Explore safety & efficacy data. Hear the experts discuss. How might early treatment decisions impact long-term outcomes in patients? Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/xoPdYAof7m https://t.co/qkD7rMozps
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: My Cancelled Lecture Slides
https://t.co/hHvszC0SFR https://t.co/SRqfM5DsT3
Links:
Dr. John Cush @RheumNow ( View Tweet)
International Osteoporosis Foundation (IOF) has developed a self-management website for people living with osteoporosis. The website focuses on providing education and resources for exercise, nutrition, home safety, and advice for care partners. https://t.co/T8TllaIipU https://t.co/V7ifRaTWZY
Links:
Dr. John Cush @RheumNow ( View Tweet)
Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy
A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early https://t.co/hYf6GiR6TN
Dr. John Cush @RheumNow ( View Tweet)
Managing Gout in CKD Patients
A current review article addressed the management of gout patients with chronic kidney disease (CKD). This full read review addresses the epidemiology, challenges, treatment decisions, and outcomes.
https://t.co/ND0cspcmDd https://t.co/HI55D5koZj
Dr. John Cush @RheumNow ( View Tweet)
NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus
A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.
https://t.co/OEuNAZlgzp https://t.co/F00L9uYEOv
Dr. John Cush @RheumNow ( View Tweet)
Long-Term Hydroxychloroquine Retinopathy Risk
About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.
https://t.co/TBSTIb29Pf https://t.co/7TYQe4N4JH
Dr. John Cush @RheumNow ( View Tweet)
Basic, full-read overview of "JAK inhibitors: risks and safety principles" from the Pharmaceutical Journal. Addresses MOA, indications, warnings, monitoring, adverse effects, interactions, Serious AEs, vaccination and best practices. https://t.co/6kZCde1NdF https://t.co/NlEKtvUGPa
Links:
Dr. John Cush @RheumNow ( View Tweet)
“We’re facing a tsunami of retiring older, white rheumatologists” – Chad Deal, MD
Dr. John Cush @RheumNow ( View Tweet)
UCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi
Dr. John Cush @RheumNow ( View Tweet)
https://t.co/4UQlqwujiR 2026 — On Demand
Catch the sessions everyone in rheumatology is talking about:
• RA advances
• Psoriatic arthritis decisions
• Spondyloarthritis updates
• Autoimmune disease highlights
• Vasculitis insights
Full recordings + slides available now. https://t.co/QT6NOXakVv
Links:
Dr. John Cush @RheumNow ( View Tweet)
Annual fibromyalgia survey (FIRST) in axSpA pts in the DESIR cohort. FM was found in 22% (& assoc w/ less HLA-B27+ & XRay sacroiliitis, equal MRI SI a& ^ CRP. FM/AxSpA had less self-reported Dz activity, QOL, more disability & more likely to Rx w/ TNFi (64% vs 41%), but resp https://t.co/9rkZFUSB2M
Dr. John Cush @RheumNow ( View Tweet)
The Role of Calcineurin Inhibitors in Lupus Nephritis
In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1). However, significant https://t.co/sc4cgAYzGy
Dr. John Cush @RheumNow ( View Tweet)
Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy
A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early https://t.co/jKCbIvfebm
Dr. John Cush @RheumNow ( View Tweet)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower serum uric acid levels, by approximately 0.6 to 1.5 mg/dL. They increase renal uric acid excretion via a uricosuric effect), thereby reducing gout risk by 30% to 50%. https://t.co/weXVOhpiP9 https://t.co/NsCRNi9JI9
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Poets Know It (3.13.2026)-
UBER Rheumatology Ride (3.6.2026)
-
UBER Rheumatology Ride (3.6.2026)
Early Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health Impact
Therapeutic Updates
5-Year Results of an IL-23 Inhibitor in Patients With PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post
Poster Hall
